Investors who suffered significant losses from their holdings in POMDoctor Ltd. (NASDAQ: POM) are being encouraged to join a class action lawsuit initiated by Robbins LLP. The lawsuit pertains to all individuals who purchased or acquired securities of POMDoctor between October 9, 2025 and December 11, 2025.
POMDoctor, which positions itself as a “leading online medical services platform for chronic diseases in China,” has been embroiled in controversy following its initial public offering (IPO) on December 10, 2025. During the weeks leading to the IPO, the company’s stock experienced a dramatic increase, climbing from an initial price of $4.00 to an all-time high of $6.09. Investigations suggest that this surge was not backed by legitimate business developments.
Allegations of Misconduct
The complaint filed by Robbins LLP outlines serious allegations against POMDoctor, including claims that the company was the target of a coordinated “pump-and-dump” scheme. According to the lawsuit, misleading information circulated on social media and online forums by impersonators posing as financial advisors encouraged retail investors to buy shares, artificially inflating the stock price.
On the day of the IPO, POMDoctor’s share price plummeted approximately 91%, dropping to $0.50 per share. Currently, the stock is trading around $0.40, reflecting ongoing investor concerns. The class action alleges that during the period in question, POMDoctor failed to disclose critical information, including:
“(i) that POMDoctor was subject to a fundamental stock promotion scheme involving social media-based misinformation; (ii) that insiders used offshore accounts to facilitate the dumping of shares; and (iii) that the company’s public statements omitted mention of false rumors and artificial trading activity.”
Next Steps for Shareholders
Shareholders who wish to take part in the class action must submit their paperwork to the court by April 7, 2026. Those chosen as lead plaintiffs will represent fellow investors in guiding the litigation. Importantly, participation in the class action is not mandatory for recovery; investors may choose to remain absent from the case while still being eligible for any potential settlements.
Robbins LLP operates on a contingency fee basis, meaning that shareholders will incur no fees or expenses unless they recover losses. Interested investors can obtain additional information by contacting attorney Aaron Dumas, Jr. via email or by calling (800) 350-6003.
Established in 2002, Robbins LLP has built a reputation for advocating shareholder rights and seeking accountability from corporate executives. The firm is dedicated to helping investors recover losses while promoting transparency and ethical governance in the companies they invest in.
For ongoing updates regarding the class action against POMDoctor Ltd. or to receive alerts about corporate misconduct, interested parties can sign up for the firm’s Stock Watch service.
As the legal proceedings unfold, investors are urged to stay informed and consider their options carefully in this evolving situation.
